Prolongation of the Interval Between Monitoring of Warfarin in Stable Patients
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00356759|
Recruitment Status : Completed
First Posted : July 26, 2006
Results First Posted : August 22, 2018
Last Update Posted : August 22, 2018
Patients with mechanical heart valve prosthesis or with irregular beat (atrial fibrillation) have a high risk of blood clot formation. Such clots can result in a stroke. The patients are treated with warfarin - a "blood thinner" - to prevent these complications. The treatment has to be monitored with a blood test called Prothrombin time (PT) every 1-4 weeks. The dose of warfarin has to be changed whenever the PT result is outside of the treatment range. If the result is too low there is an increased risk of blood clots. If, instead, the result is too high there is a risk of bleeding. One third of the patients have very stable PT results and hardly ever have to change the dose.
The investigators hypothesis is that these patients can go less often, e.g. every 12 weeks, for the blood tests.
|Condition or disease||Intervention/treatment||Phase|
|Atrial Fibrillation Heart Valve Diseases Venous Thrombosis||Drug: Dosing warfarin every 12 weeks, sham INRs 2 out of 3 times||Phase 2|
OBJECTIVE: The PRolongation of the INTerval between prothrombin time tests in stable patients (PRINT) is a single center, randomized, double-blind study to demonstrate that testing the prothrombin time every 12 weeks provides the same level of anticoagulant control as conventional testing every 4 weeks in this subset of stable patients. This study will enroll patients who have been treated with vitamin K antagonists (VKA) for at least 6 months and have not had any change to the maintenance dose for the most recent 6 months.
HYPOTHESIS: Our hypothesis is that by extending the interval between tests to 12 weeks in these stable patients, the same level of anticoagulant control, can be maintained. With the large and constantly increasing number of patients on warfarin, a reduced frequency of testing would yield considerable savings for the health care system and a decreased burden for the patient. A review of our anticoagulant clinic revealed that one third of the patients would be eligible for such a prolongation of the test interval.
STUDY DESIGN: The proposal is a randomized, double-blind, controlled single centre trial performed at Hamilton Health Sciences - General Hospital. Main inclusion criteria are: long-term anticoagulant therapy, managed by our clinic for at least 6 months and with unchanged maintenance dose for at least 6 months. Eligible and consenting patients identified at annual review visits or from the register of patients monitored by the clinic, will be randomized to dosing of warfarin every 4 weeks (control) or every 12 weeks (experimental). All patients will, however, have blood drawn every 4 weeks. Randomization will be performed using a computer-generated randomization sequence. Stratification is done for the two laboratories performing the analysis and for the two therapeutic ranges that patients are to be maintained within, depending on the indication for anticoagulation. Patients with mechanical mitral valve prosthesis are maintained between 2.5 and 3.5, others between 2.0 and 3.0.The randomization sequence will guide the Coordinating and Methods Center to the correct reporting procedure for each patient, and to provide sham INR-values for two out of each set of three 4-weekly tests in the patients allocated to 12-weekly monitoring. Extreme INR results (<1.5 or >4.4) will always be reported as true results. The investigator and the patient are blind to the procedure and are only aware of the sequence order number.The patients are carefully instructed about risk factors that can change the effect of VKA. They are contacted by telephone after each test for information on the result, the dosing and for questioning of adverse events. After 12 months in the study there is a final visit scheduled at the anticoagulation clinic for review of the patient.
ANALYSIS: After the last patient has concluded the study, all clinical data will be transferred to the study statistician for analysis. The primary outcome measure is "the time in therapeutic range" (TTR). The secondary outcome measures are "proportion of patients with extreme INR results", "proportion of INR results that are extreme" and "number of changes of the maintenance dose". These are well-recognized tools for evaluation of the level of anticoagulant control. Major bleeding and objectively verified thromboembolic events will also be registered, but the expected number is very small and not sufficient for any statistical analyses.
SAMPLE SIZE: Sample size calculations are based on 77% TTR for a population with very stable VKA-dose and a maximum tolerable deviation of 7.5 percentage points; one-sided alpha of 2.5% and power of 90%. The sample will accordingly be 107 patients per group. After interim analysis the DSMB recommended to expand the sample size to 125 patients per group (July 16, 2008).
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||250 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Triple (Participant, Care Provider, Investigator)|
|Official Title:||A Randomized Double-blind Study of 4-weekly Versus 12-weekly Monitoring of Stable Patients on Long-term Anticoagulation With Warfarin|
|Study Start Date :||December 2006|
|Actual Primary Completion Date :||January 2010|
|Actual Study Completion Date :||February 2010|
Sham Comparator: 12-weekly INR
Dosing warfarin every 12 weeks, sham INRs 2 out of 3 times
Drug: Dosing warfarin every 12 weeks, sham INRs 2 out of 3 times
Warfarin is dosed according to INR to maintain INR 2.0-3.0 or for mechanical mitral valves or mechanical aortic valves with atrial fibrillation INR 2.5-3.5
Other Name: warfarin, Coumadin
No Intervention: Standard management
Dosing warfarin every 4 weeks, all INRs true values
- Primary Outcome Measure: Time in Therapeutic Range [ Time Frame: 12 months ]Percent time in therapeutic range calculated by linear interpolation.
- Secondary Efficacy Outcomes: Thromboembolic Events [ Time Frame: 12 months ]Number of patients with any objectively verified, independently adjudicated thromboembolic event during the 12-month study period
- Secondary Safety Outcome: Major Bleeding [ Time Frame: 12 months ]Number of patients with any objectively verified, independently adjudicated major bleeding event during the 12-month study period. Major bleeding was defined according to the International Society on Thrombosis and Haemostasis (ISTH) criteria
- Secondary Safety Outcome: Number of Patients With Extreme INR Results [ Time Frame: 12 months ]Secondary safety outcome is number of patients with at least one INR below 1.5 or above 4.4
- Number of Extreme INR Results [ Time Frame: 12 months ]Number of INRs outside the range 1.5-4.4
- Patients With Dose Changes [ Time Frame: 12 months ]Number of patients with at least one change of maintenance dose during the 12-month study period
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00356759
|HHS - General Hospital, Thrombosis Service|
|Hamilton, Ontario, Canada, L8L 2X2|
|Principal Investigator:||Sam Schulman, Professor||McMaster University|